Neomas

Neomas may be available in the countries listed below.

Ingredient matches for Neomas

Neomycin

Neomycin sulfate (a derivative of Neomycin) is reported as an ingredient of Neomas in the following countries:

• Argentina

International Drug Name Search

Fladystin

Fladystin may be available in the countries listed below.

Ingredient matches for Fladystin

Metronidazole

Metronidazole is reported as an ingredient of Fladystin in the following countries:

• Indonesia

Nystatin

Nystatin is reported as an ingredient of Fladystin in the following countries:

• Indonesia

International Drug Name Search

Naltrexone aop

Naltrexone aop may be available in the countries listed below.

Ingredient matches for Naltrexone aop

Naltrexone

Naltrexone is reported as an ingredient of Naltrexone aop in the following countries:

• Lithuania

International Drug Name Search

Winpain

Winpain may be available in the countries listed below.

Ingredient matches for Winpain

Tramadol

Tramadol hydrochloride (a derivative of Tramadol) is reported as an ingredient of Winpain in the following countries:

• Bangladesh

International Drug Name Search

Recustein

Recustein may be available in the countries listed below.

Ingredient matches for Recustein

Erdosteine

Erdosteine is reported as an ingredient of Recustein in the following countries:

• Indonesia

International Drug Name Search

Dopasol

Dopasol may be available in the countries listed below.

Ingredient matches for Dopasol

Levodopa

Levodopa is reported as an ingredient of Dopasol in the following countries:

• Japan

International Drug Name Search

Risumic

Risumic may be available in the countries listed below.

Ingredient matches for Risumic

Amezinium Metilsulfate

Amezinium Metilsulfate is reported as an ingredient of Risumic in the following countries:

• Japan

International Drug Name Search

Doribax

Generic Name: Doripenem
Class: Carbapenems
Chemical Name: (4R,5S,6S)-3-[((3S,5S)-5-[[(aminosulfonyl)amino] methyl]-3-pyrrolidinyl)thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo [3.2.0]hept-2-ene-2-carboxylic acid monohydrate.
Molecular Formula: C₁₅H₂₄N₄O₆S₂
CAS Number: 148016-81-3

Introduction

Antibacterial; carbapenem β-lactam antibiotic.^{1 3}

Uses for Doribax

Intra-abdominal Infections

Treatment of complicated intra-abdominal infections caused by susceptible Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, B. caccae, B. thetaiotaomicron, B. uniformis, B. vulgatus, Streptococcus intermedius, S. constellatus, or Peptostreptococcus micros.^{1 2 10}

Urinary Tract Infections

Treatment of complicated urinary tract infections (including pyelonephritis) caused by susceptible E. coli (including cases with concurrent bacteremia) or susceptible K. pneumoniae, Proteus mirabilis, Ps. aeruginosa, or Acinetobacter baumannii.^{1 10}

Respiratory Tract Infections

Has been used for treatment of bronchopulmonary infection in patients with cystic fibrosis who are colonized with Ps. aeruginosa or Burkholderia cepacia† (designated an orphan drug by FDA for this use).¹⁶

Has been used for treatment of nosocomial pneumonia†, including ventilator-associated pneumonia† (VAP).^{6 13 14}

Doribax Dosage and Administration

Administration

Administer by IV infusion.¹

Not for administration via inhalation.¹ (See Pneumonitis under Cautions.)

For solution and drug compatibility information, see Compatibility under Stability.

IV Administration

Reconstitution

Use strict aseptic technique since drug product contains no preservative.¹

Reconstitute vial containing 500 mg of doripenem with 10 mL of sterile water for injection or 0.9% sodium chloride injection; shake gently to provide a suspension containing 50 mg/mL.¹

Reconstituted suspension is not for direct injection; must be further diluted in ≤1 hour following reconstitution.¹ (See Storage under Stability.)

Dilution

For a 500-mg dose, withdraw contents of the reconstituted vial with a 21-gauge needle and add it to an infusion bag containing 100 mL of 0.9% sodium chloride injection or 5% dextrose for injection to provide a solution containing 500 mg (4.5 mg/mL); gently shake until clear.¹

For a 250-mg dose, withdraw contents of the reconstituted vial with a 21-gauge needle and add it to an infusion bag containing 100 mL of 0.9% sodium chloride injection or 5% dextrose for injection; gently shake until clear.¹ Remove and discard 55 mL of the solution from the bag to provide a solution containing 250 mg (4.5 mg/mL).¹

Rate of Administration

Administer by IV infusion over 1 hour.¹

Dosage

Available as doripenem monohydrate; dosage expressed in terms of doripenem.¹

Adults

Intra-abdominal Infections

IV

500 mg every 8 hours.¹ Usual duration is 5–14 days; treatment may be switched to an appropriate oral anti-infective after ≥3 days, if clinical improvement has been demonstrated.¹

Urinary Tract Infections

IV

500 mg every 8 hours.¹ Usual duration is 10 days but may be extended up to 14 days for patients with concurrent bacteremia; treatment may be switched to an appropriate oral anti-infective after ≥3 days, if clinical improvement has been demonstrated.¹

Special Populations

Hepatic Impairment

No specific dosage recommendations at this time.¹

Renal Impairment

Dosage adjustment recommended in patients with Cl_cr ≤50 mL/minute.¹

Dosage for Adults with Renal Impairment1

Clcr (mL/minute)	Daily Dosage
30–50	250 mg every 8 hours
11–29	250 mg every 12 hours

Insufficient data to recommend dosage adjustments in patients undergoing hemodialysis.¹

Geriatric Patients

No dosage adjustments except those related to renal impairment.¹ (See Renal Impairment under Dosage and Administration.)

Cautions for Doribax

Contraindications

• 
  

  Known hypersensitivity to doripenem or other carbapenems.¹

  
  


• 
  

  History of anaphylactic reaction to β-lactams.¹

  
  

Warnings/Precautions

Warnings

Superinfection/Clostridium difficile-associated Diarrhea and Colitis

Treatment with anti-infectives may permit overgrowth of Clostridium difficile.^{1 19 20 21 22 23} C. difficile-associated diarrhea and colitis (CDAD; also known as antibiotic-associated diarrhea and colitis or pseudomembranous colitis) has been reported with nearly all anti-infectives and may range in severity from mild diarrhea to fatal colitis.¹

Consider CDAD if diarrhea develops during or after therapy and manage accordingly.^{1 19 20 21 22 23} Obtain a careful medical history since CDAD may occur as late as ≥2 months after anti-infective therapy is discontinued.¹

If CDAD is suspected or confirmed, the anti-infective may need to be discontinued.¹ Manage moderate to severe cases with fluid, electrolyte, and protein supplementation; appropriate anti-infective therapy (e.g., oral metronidazole or vancomycin); and surgical evaluation when clinically indicated.^{1 19 20 21 22 23}

Selection and Use of Anti-infectives

Use only for treatment or prevention of infections proven or strongly suspected to be caused by susceptible bacteria.¹

Use results of culture and in vitro susceptibility testing.¹ If such data are unavailable, consider local epidemiology and susceptibility patterns when selecting anti-infectives for empiric therapy.¹

Pneumonitis

Pneumonitis reported following administration by inhalation†;¹ not for inhalation administration.¹

Interaction with Valproic Acid

Doripenem reduces valproic acid serum concentrations to subtherapeutic concentrations; possible increased risk of seizures.^a Monitor serum valproic acid concentrations and consider alternative therapies.^a (See Specific Drugs under Interactions.)

Sensitivity Reactions

Hypersensitivity Reactions

Serious and occasionally fatal hypersensitivity reactions (e.g., anaphylaxis) and serious skin reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis) reported.¹

If hypersensitivity occurs, discontinue doripenem and institute appropriate therapy as indicated (e.g., epinephrine, corticosteroids, IV fluids, IV antihistamines, pressor amines, oxygen and maintenance of an adequate airway).¹

Cross-hypersensitivity

Cross-allergenicity occurs among β-lactam antibiotics, including penicillins, cephalosporins, and other β-lactams.¹

Prior to initiation of therapy, make careful inquiry concerning previous hypersensitivity reactions to doripenem, cephalosporins, penicillins, or other drugs.¹

General Precautions

CNS Effects

Seizures and other CNS effects (e.g., confusional states, myoclonic activity) reported with carbapenems (e.g., ertapenem, imipenem, meropenem), especially in those with underlying CNS disorders (e.g., brain lesions, history of seizures) and/or compromised renal function.^{8 10 24 25 26}

Rarely, seizures reported in patients receiving doripenem;¹ causality not established.¹

Specific Populations

Pregnancy

Category B.¹

Lactation

Not known if doripenem is distributed into milk.¹ Use with caution.¹

Pediatric Use

Safety and efficacy not established in patients <18 years of age.¹

Geriatric Use

No substantial differences in safety relative to younger adults, but increased sensitivity cannot be ruled out.¹

Substantially eliminated by kidneys; risk of adverse reactions may be greater in geriatric patients with impaired renal function or prerenal azotemia.¹ Select dosage with caution and assess renal function periodically since geriatric patients are more likely to have renal impairment.¹

Hepatic Impairment

Pharmacokinetics not established but impact of hepatic impairment should be minimal.¹

Renal Impairment

Increased AUC.¹ Dosage adjustments and monitoring of renal function recommended in patients with moderate or severe renal impairment (Cl_cr ≤50 mL/minute).¹ (See Special Populations under Dosage and Administration.)

Risk of adverse reactions may be greater in patients with impaired renal function.¹

Common Adverse Effects

Headache, nausea, diarrhea, rash, phlebitis.¹

Interactions for Doribax

Drugs Affecting or Metabolized by Hepatic Microsomal Enzymes

Does not inhibit CYP isoenzymes 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, 3A4/5, or 4A11.¹ Not expected to induce CYP1A2, 2B6, 2C9, 2C19, or 3A4/5.¹ Pharmacokinetic interactions unlikely with drugs metabolized by these isoenzymes.¹

Drugs Metabolized by Uridine Diphosphate-glucuronosyltransferase (UGT) 1A1

Not expected to induce UGT 1A1;¹ pharmacokinetic interactions unlikely with drugs metabolized by this enzyme.¹

Specific Drugs

Drug	Interaction	Comments
Anti-infective agents (e.g., amikacin, co-trimoxazole, daptomycin, levofloxacin, linezolid, vancomycin)	Minimal potential to antagonize or be antagonized by other anti-infectives1 10
Probenecid	Decreased renal tubular secretion of doripenem; increased doripenem concentrations, AUC, and prolonged half-life1	Concomitant use not recommended1
Valproic acid	Concomitant administration decreases valproic acid to subtherapeutic concentrations; AUC reduced by 63% a Pharmacokinetics of doripenem unaffecteda	Monitor serum valproic acid concentrations if administered concomitantly;a consider alternative anti-infective or anticonvulsant therapya

Doribax Pharmacokinetics

Distribution

Extent

Distributed into intra-abdominal tissues and fluids (e.g., retroperitoneal fluid,¹ peritoneal exudate,^{1 11} bile,¹ gallbladder tissue,¹ urine).¹

Not known if doripenem is distributed into milk.¹

Plasma Protein Binding

Approximately 8.1%.¹

Elimination

Metabolism

Partially metabolized to an inactive ring-opened metabolite (doripenem M1) principally via dehydropeptidase-I.¹

Not metabolized by CYP isoenzymes.¹

Elimination Route

Excreted principally in urine as unchanged drug (70%).¹

Half-life

Approximately 1 hour.¹

Special Populations

Pharmacokinetics in patients with hepatic impairment not established.¹

Removed by hemodialysis.¹

AUC increased in patients with renal impairment.¹

Stability

Storage

Parenteral

Powder for Injection

25°C (may be exposed to 15–30°C).¹

Reconstituted suspension containing 50 mg/mL, in sterile water for injection or 0.9% sodium chloride injection, is stable for ≤1 hour; do not freeze.¹

Diluted IV solutions prepared using 0.9% sodium chloride injection or 5% dextrose for injection are stable for 8 or 4 hours, respectively, at room temperature (including infusion time) or 24 hours at 2–8°C (including infusion time); do not freeze.¹

Compatibility

For information on systemic interactions resulting from concomitant use, see Interactions.

Parenteral

Solution Compatibility¹

Compatible
Dextrose 5% in water
Sodium chloride 0.9%
Sterile water for injection

Drug Compatibility

Compatibility with other drugs not established.¹ Do not mix with or add to solutions containing other drugs.¹

Actions and SpectrumActions

• 
  

  Synthetic carbapenem β-lactam antibiotic; structurally and pharmacologically related to ertapenem, imipenem, and meropenem.^{1 3}

  
  


• 
  

  Usually bactericidal in action.¹

  
  


• 
  

  Like other β-lactam antibiotics, antibacterial activity results from inhibition of bacterial cell wall synthesis.^{1 3 10}

  
  


• 
  

  Spectrum of activity includes many aerobic and anaerobic gram-positive and gram-negative bacteria.^{1 3 4 5 10}

  
  


• 
  

  Reported as more active than some other carbapenems against Enterobacteriaceae and Ps. aeruginosa.^{2 3 4 9 10 12 18}

  
  


• 
  

  Gram-positive aerobes: Active in vitro and in clinical infections against Streptococcus intermedius¹ and S. constellatus.¹ Also active in vitro against Staphylococcus aureus (including oxacillin-susceptible [methicillin-susceptible] strains),^{1 4} S. epidermidis,⁴ S. agalactiae (group B streptococci),^{1 4} and S. pyogenes (group A β-hemolytic streptococci).¹ Oxacillin-resistant (methicillin-resistant) staphylococci are resistant.¹

  
  


• 
  

  Gram-negative aerobes: Active in vitro and in clinical infections against E. coli,^{1 4} Klebsiella pneumoniae,^{1 4} Proteus mirabilis,^{1 4} Ps. aeruginosa,^{1 4} and Acinetobacter baumannii.¹ Also active in vitro against Citrobacter freundii,¹ Enterobacter cloacae,^{1 4} E. aerogenes,^{1 4} K. oxytoca,^{1 4} Morganella morganii,¹ and Serratia marcescens¹ and some strains of Burkholderia cepacia.^{17 18}

  
  


• 
  

  Anaerobes: Active in vitro and in clinical infections against Bacteroides fragilis,^{1 4 5} B. caccae,^{1 4} B. thetaiotaomicron,^{1 4 5} B. uniformis,^{1 4} B. vulgatus,^{1 4} and Peptostreptococcus micros.^{1 4 5}

  
  


• 
  

  Cross-resistance may occur with other carbapenems; however, some isolates (e.g., some strains of Ps. aeruginosa) resistant to other carbapenems may be susceptible to doripenem.^{1 4}

  
  

Advice to Patients

• 
  

  Advise patients that antibacterials (including doripenem) should only be used to treat bacterial infections and not used to treat viral infections (e.g., the common cold).¹

  
  


• 
  

  Importance of completing full course of therapy, even if feeling better after a few days.¹

  
  


• 
  

  Advise patients that skipping doses or not completing the full course of therapy may decrease effectiveness and increase the likelihood that bacteria will develop resistance and will not be treatable with doripenem or other antibacterials in the future.¹

  
  


• 
  

  Importance of informing clinicians of any previous hypersensitivity reactions to doripenem, other carbapenems, β-lactams, or other allergens.¹

  
  


• 
  

  Importance of discontinuing therapy and informing clinician if an allergic or hypersensitivity reaction occurs.¹

  
  


• 
  

  Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, and any concomitant illnesses.¹

  
  


• 
  

  Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.¹

  
  


• 
  

  Importance of informing patients of other important precautionary information.¹ (See Cautions.)

  
  

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Doripenem (Monohydrate)

Routes	Dosage Forms	Strengths	Brand Names	Manufacturer
Parenteral	For injection, for IV infusion	500 mg (of doripenem)	Doribax	Ortho-McNeil

Disclaimer

This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.

The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.

AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions August 2009. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.

† Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

1. Ortho-McNeil, Inc. Doribax (doripenem for injection) prescribing information. Raritan, NJ; 2008 Jan.

2. Lucasti C, Jasovich A, Umeh O et al. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study. Clin Ther. 2008; 30:868-83. [PubMed 18555934]

3. Zhanel GG, Wiebe R, Dilay L et al. Comparative review of the carbapenems. Drugs. 2007; 67:1027-52. [PubMed 17488146]

4. Goldstein EJ, Citron DM, Merriam CV et al. In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. Antimicrob Agents Chemother. 2008; 52:761-6. [PubMed 18070958]

5. Wexler HM, Engel AE, Glass D et al. In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates. Antimicrob Agents Chemother. 2005; 49:4413-7. [PubMed 16189137]

6. Ortho-McNeil, Inc, Titusville, NJ: Personal communication.

7. Naber K, Redman R, Kotey P et al. Intravenous therapy with doripenem versus levofloxacin with an option for oral step-down therapy in the treatment of complicated urinary tract infections and pyelonephritis. Int J Antimicrob Agents. 2007; 29:S212.

8. Horiuchi M, Kimura M, Tokumura M et al. Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with beta-lactam antibiotics. Toxicology. 2006; 222:114-24. [PubMed 16549226]

9. Hagerman JK, Knechtel SA, Klepser ME. Doripenem: a new extended-spectrum carbapenem antibiotic. Formulary. 2007; 42:676-88.

10. Nicolau DP. Carbapenems: a potent class of antibiotics. Expert Opin Pharmacother. 2008; 9:23-37. [PubMed 18076336]

11. Ikawa K, Morikawa N, Urakawa N et al. Peritoneal penetration of doripenem after intravenous administration in abdominal-surgery patients. J Antimicrob Chemother. 2007; 60:1395-7. [PubMed 17884833]

12. Mesaros N, Nordmann P, Plésiat P et al. Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clin Microbiol Infect. 2007; 13:560-78. [PubMed 17266725]

13. Réa-Neto A, Niederman M, Lobo SM et al. Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study. Curr Med Res Opin. 2008; 24:2113-26. [PubMed 18549664]

14. Chastre J, Wunderink R, Prokocimer P et al. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med. 2008; 36:1089-96. [PubMed 18379232]

15. Davies TA, Shang W, Bush K et al. Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2008; 52:1510-2. [PubMed 18250190]

16. Food and Drug Administration. Orphan designations pursuant to Section 526 of the Federal Food and Cosmetic Act as amended by the Orphan Drug Act (P.L. 97-414). Rockville, MD; 2004 July. From FDA web site (). Accessed August 2008.

17. Chen Y, Garber E, Zhao Q et al. In vitro activity of doripenem (S-4661) against multidrug-resistant gram-negative bacilli isolated from patients with cystic fibrosis. Antimicrob Agents Chemother. 2005; 49:2510-1. [PubMed 15917558]

18. Traczewski MM, Brown SD. In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients. Antimicrob Agents Chemother. 2006; 50:819-21. [PubMed 16436756]

19. Johnson S, Gerding DN. Clostridium difficile-associated diarrhea. Clin Infect Dis. 1998; 26:1027-36. [IDIS 407733] [PubMed 9597221]

20. Gerding DN, Johnson S, Peterson LR et al for the Society for Healthcare Epidemiology of America. Position paper on Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol. 1995; 16:459-77. [PubMed 7594392]

21. Fekety R for the American College of Gastroenterology Practice Parameters Committee. Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. Am J Gastroenterol. 1997; 92:739-50. [IDIS 386628] [PubMed 9149180]

22. American Society of Health-System Pharmacists Commission on Therapeutics. ASHP therapeutic position statement on the preferential use of metronidazole for the treatment of Clostridium difficile-associated disease. Am J Health-Syst Pharm. 1998; 55:1407-11. [IDIS 407213] [PubMed 9659970]

23. Wilcox MH. Treatment of Clostridium difficile infection. J Antimicrob Chemother. 1998; 41(Suppl C):41-6. [IDIS 407246] [PubMed 9630373]

24. Merck & Co., Inc. Invanz (ertapenem) for injection prescribing information. Whitehouse Station, NJ; 2008 Feb.

25. Merck & Co., Inc. Primaxin I.V. (imipenem and cilastatin) for injection prescribing information. Whitehouse Station, NJ; 2007 Dec.

26. AstraZeneca. Merrem I.V. (meropenem) for injection for intravenous use only prescribing information. Wilmington, DE; 2008 Mar.

27. A multicenter, phase 3 study to confirm the safety and efficacy of intravenous doripenem in complicated lower urinary tract infection or pyelonephritis (JNJ-38 174942 DORI-06 CR005398). From National Institutes of Health clinical trials website (). Accessed 2008 Sep 26.

a. Ortho-McNeil, Inc. Doribax (doripenem for injection) prescribing information. Raritan, NJ; 2008 Oct.

More Doribax resources

• Doribax Side Effects (in more detail)
• Doribax Use in Pregnancy & Breastfeeding
• Doribax Drug Interactions
• Doribax Support Group
• 0 Reviews for Doribax - Add your own review/rating

• Doribax Prescribing Information (FDA)


• Doribax Consumer Overview


• Doribax Advanced Consumer (Micromedex) - Includes Dosage Information


• Doribax MedFacts Consumer Leaflet (Wolters Kluwer)


• Doripenem Professional Patient Advice (Wolters Kluwer)

Compare Doribax with other medications

• Intraabdominal Infection
• Kidney Infections
• Urinary Tract Infection

Oculerge

Oculerge may be available in the countries listed below.

Ingredient matches for Oculerge

Antazoline

Antazoline hydrochloride (a derivative of Antazoline) is reported as an ingredient of Oculerge in the following countries:

• South Africa

Tetryzoline

Tetryzoline hydrochloride (a derivative of Tetryzoline) is reported as an ingredient of Oculerge in the following countries:

• South Africa

International Drug Name Search

Sultrival

Sultrival may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Sultrival

Sulfadiazine

Sulfadiazine is reported as an ingredient of Sultrival in the following countries:

• France

Sulfadiazine sodium (a derivative of Sulfadiazine) is reported as an ingredient of Sultrival in the following countries:

• France

Trimethoprim

Trimethoprim is reported as an ingredient of Sultrival in the following countries:

• France

International Drug Name Search

Adco-Amoxycillin

Adco-Amoxycillin may be available in the countries listed below.

Ingredient matches for Adco-Amoxycillin

Amoxicillin

Amoxicillin trihydrate (a derivative of Amoxicillin) is reported as an ingredient of Adco-Amoxycillin in the following countries:

• South Africa

International Drug Name Search

Taubenheil

Taubenheil may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Taubenheil

Methenamine

Methenamine is reported as an ingredient of Taubenheil in the following countries:

• Germany

International Drug Name Search

Supprelin LA

Supprelin LA is a brand name of histrelin, approved by the FDA in the following formulation(s):

SUPPRELIN LA (histrelin acetate - implant; subcutaneous)

• 
  Manufacturer: ENDO PHARM
  
  Approval date: May 3, 2007
  
  Strength(s): 50MG ^[RLD]

Has a generic version of Supprelin LA been approved?

No. There is currently no therapeutically equivalent version of Supprelin LA available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Supprelin LA. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Compositions and methods for treating precocious puberty
  Patent 8,062,652
  Issued: November 22, 2011
  Inventor(s): Kuzma; Petr
  Assignee(s): Endo Pharmaceuticals Solutions Inc.
  The present invention is directed to the controlled delivery of gonadotropin-releasing hormone (GnRH) agonists, preferably from a polymeric material that is implanted in the body. More specifically, the present invention relates to compositions comprised of a GnRH agonist, preferably histrelin, in a polymeric material that results in a desired and controlled delivery of a therapeutically effective amount of GnRH agonist over an extended period of time in order to treat central precocious puberty (CPP).
  
  Patent expiration dates:
  
  
  • June 16, 2026
    
    ✓ 
    Patent use: METHOD OF TREATMENT OF CHILDREN WITH CENTRAL PRECOCIOUS PUBERTY
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • May 3, 2014 - ORPHAN DRUG EXCLUSIVITY
  
  

See also...

• Supprelin LA Implant Consumer Information (Wolters Kluwer)
• Supprelin LA implant Consumer Information (Cerner Multum)
• Supprelin LA Advanced Consumer Information (Micromedex)
• Supprelin-LA Consumer Information (Drugs.com)
• Histrelin Implant Consumer Information (Wolters Kluwer)
• Histrelin implant Consumer Information (Cerner Multum)
• Histrelin Subcutaneous Advanced Consumer Information (Micromedex)
• Histrelin acetate Subcutaneous Advanced Consumer Information (Micromedex)
• Histrelin AHFS DI Monographs (ASHP)

Risnia

Risnia may be available in the countries listed below.

Ingredient matches for Risnia

Risperidone

Risperidone is reported as an ingredient of Risnia in the following countries:

• Croatia (Hrvatska)


• Georgia


• Sri Lanka

International Drug Name Search

Elplat

Elplat may be available in the countries listed below.

Ingredient matches for Elplat

Oxaliplatin

Oxaliplatin is reported as an ingredient of Elplat in the following countries:

• Japan

International Drug Name Search

Wick Formel 44 Plus Hustenstiller

Wick Formel 44 Plus Hustenstiller may be available in the countries listed below.

Ingredient matches for Wick Formel 44 Plus Hustenstiller

Dextromethorphan

Dextromethorphan hydrobromide (a derivative of Dextromethorphan) is reported as an ingredient of Wick Formel 44 Plus Hustenstiller in the following countries:

• Austria

International Drug Name Search

Volmatik

Volmatik may be available in the countries listed below.

Ingredient matches for Volmatik

Diclofenac

Diclofenac sodium salt (a derivative of Diclofenac) is reported as an ingredient of Volmatik in the following countries:

• Indonesia

International Drug Name Search

Maygace Altas Dosis

Maygace Altas Dosis may be available in the countries listed below.

Ingredient matches for Maygace Altas Dosis

Megestrol

Megestrol 17α-acetate (a derivative of Megestrol) is reported as an ingredient of Maygace Altas Dosis in the following countries:

• Spain

International Drug Name Search

Roxene

Roxene may be available in the countries listed below.

Ingredient matches for Roxene

Piroxicam

Piroxicam is reported as an ingredient of Roxene in the following countries:

• Italy

International Drug Name Search

Sintotrat

Sintotrat may be available in the countries listed below.

Ingredient matches for Sintotrat

Hydrocortisone

Hydrocortisone 21-acetate (a derivative of Hydrocortisone) is reported as an ingredient of Sintotrat in the following countries:

• Italy

International Drug Name Search

Megacef

Megacef may be available in the countries listed below.

Ingredient matches for Megacef

Cefixime

Cefixime is reported as an ingredient of Megacef in the following countries:

• Tunisia

International Drug Name Search

Thaled

Thaled may be available in the countries listed below.

Ingredient matches for Thaled

Thalidomide

Thalidomide is reported as an ingredient of Thaled in the following countries:

• Japan

International Drug Name Search

Clomipramine HCl CF

Clomipramine HCl CF may be available in the countries listed below.

Ingredient matches for Clomipramine HCl CF

Clomipramine

Clomipramine hydrochloride (a derivative of Clomipramine) is reported as an ingredient of Clomipramine HCl CF in the following countries:

• Netherlands

International Drug Name Search

Riva-Amoxicillin

Generic Name: amoxicillin (Oral route)

a-mox-i-SIL-in

Commonly used brand name(s)

In the U.S.

• Amoxicot


• Amoxil


• DisperMox


• Moxatag


• Moxilin


• Trimox

In Canada

• Amoxil Pediatric


• Apo-Amoxi


• Apo-Amoxi Sugar-Free


• Gen-Amoxicillin


• Med Amoxicillin


• Novamoxin


• Novamoxin Reduced Sugar


• Nu-Amoxi


• Riva-Amoxicillin


• Scheinpharm Amoxicillin


• Zimamox

Available Dosage Forms:

• Tablet


• Tablet, Chewable


• Tablet for Suspension


• Powder for Suspension


• Tablet, Extended Release


• Capsule

Therapeutic Class: Antibiotic

Pharmacologic Class: Penicillin, Aminopenicillin

Uses For Riva-Amoxicillin

Amoxicillin is used to treat bacterial infections in many different parts of the body. It is also used with other medicines (e.g., clarithromycin, lansoprazole) to treat H. pylori infection and duodenal ulcers.

Amoxicillin belongs to the group of medicines known as penicillin antibiotics. It works by killing the bacteria and preventing their growth. However, this medicine will not work for colds, flu, or other virus infections.

This medicine is available only with your doctor's prescription.

Before Using Riva-Amoxicillin

In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:

Allergies

Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.

Pediatric

Appropriate studies performed to date have not demonstrated pediatric-specific problems that would limit the usefulness of amoxicillin in children. However, newborns and infants 3 months of age and younger have incompletely developed kidney functions, which may need a lower dose of this medicine.

Geriatric

Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of amoxicillin in the elderly. However, elderly patients are more likely to have age-related kidney problems, which may require caution and an adjustment in the dose for patients receiving amoxicillin.

Pregnancy

	Pregnancy Category	Explanation
All Trimesters	B	Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate studies in pregnant women OR animal studies have shown an adverse effect, but adequate studies in pregnant women have failed to demonstrate a risk to the fetus.

Breast Feeding

Studies in women suggest that this medication poses minimal risk to the infant when used during breastfeeding.

Interactions with Medicines

Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are taking this medicine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.

Using this medicine with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.

• Methotrexate


• Venlafaxine

Using this medicine with any of the following medicines may cause an increased risk of certain side effects, but using both drugs may be the best treatment for you. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.

• Acenocoumarol


• Desogestrel


• Dienogest


• Drospirenone


• Estradiol Cypionate


• Estradiol Valerate


• Ethinyl Estradiol


• Ethynodiol Diacetate


• Etonogestrel


• Khat


• Levonorgestrel


• Medroxyprogesterone Acetate


• Mestranol


• Norelgestromin


• Norethindrone


• Norgestimate


• Norgestrel


• Probenecid


• Warfarin

Interactions with Food/Tobacco/Alcohol

Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.

Other Medical Problems

The presence of other medical problems may affect the use of this medicine. Make sure you tell your doctor if you have any other medical problems, especially:

• Allergy to penicillins or cephalosporin antibiotics (e.g., cefaclor, cefadroxil, cephalexin, Ceftin®, or Keflex®) or


• Mononucleosis (viral infection)—Should not be used in patients with these conditions.

• Kidney disease, severe—Use with caution. The effects may be increased because of slower removal of the medicine from the body.

• Phenylketonuria (PKU)—The chewable tablet contains phenylalanine, which can make this condition worse.

Proper Use of amoxicillin

This section provides information on the proper use of a number of products that contain amoxicillin. It may not be specific to Riva-Amoxicillin. Please read with care.

Take this medicine only as directed by your doctor. Do not take more of it, do not take it more often, and do not take it for a longer time than your doctor ordered.

You may take this medicine with or without food.

For patients using the oral liquid:

• Shake the bottle well before each use. Measure the dose with a marked measuring spoon, oral syringe, or medicine cup. The average household teaspoon may not hold the right amount of liquid.


• You may mix the oral liquid with a baby formula, milk, fruit juice, water, ginger ale, or another cold drink. Be sure the child drinks all of the mixture immediately.

Keep using this medicine for the full treatment time, even if you feel better after the first few doses. Your infection may not clear up if you stop using the medicine too soon.

Dosing

The dose of this medicine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so.

The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.

• For oral dosage forms (capsules, powder for suspension, and tablets):
  
  • For bacterial infections:
    
    • Adults, teenagers, and children weighing 40 kilograms (kg) or more—250 to 500 milligrams (mg) every 8 hours, or 500 to 875 mg every 12 hours.
    
    
    • Children and infants older than 3 months of age weighing less than 40 kg—Dose is based on body weight and must be determined by your doctor. The usual dose is 20 to 40 milligrams (mg) per kilogram (kg) of body weight per day, divided and given every 8 hours, or 25 to 45 mg per kg of body weight per day, divided and given every 12 hours.
    
    
    • Infants 3 months of age and younger—Dose is based on body weight and must be determined by your doctor. The usual dose is 30 mg per kg of body weight per day, divided and given every 12 hours.
    
    
  
  
  • For treatment of gonorrhea:
    
    • Adults, teenagers, and children weighing 40 kilograms (kg) or more—3-grams (g) taken as a single dose.
    
    
    • Children 2 years of age and older weighing less than 40 kg—Dose is based on body weight and must be determined by your doctor. The usual dose is 50 milligrams (mg) per kilogram (kg) of body weight per day, combined with 25 mg per kg of probenecid, taken as a single dose.
    
    
    • Children younger than 2 years of age—Use is not recommended.
    
    
  
  
  • For treatment of H. pylori infection:
    
    • Adults—
      
      • Dual therapy: 1000 milligrams (mg) of amoxicillin and 30 mg of lansoprazole, each given three times a day (every 8 hours) for 14 days.
      
      
      • Triple therapy: 1000 mg of amoxicillin, 500 mg of clarithromycin, and 30 mg of lansoprazole, all given two times a day (every 12 hours) for 14 days.
      
      
    
    
    • Children—Use and dose must be determined by your doctor.
    
    
  
  

Missed Dose

If you miss a dose of this medicine, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double doses.

Storage

Keep out of the reach of children.

Do not keep outdated medicine or medicine no longer needed.

Ask your healthcare professional how you should dispose of any medicine you do not use.

Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.

You may store the oral liquid in the refrigerator. Throw away any unused medicine after 14 days. Do not freeze.

Precautions While Using Riva-Amoxicillin

If your or your child's symptoms do not improve within a few days, or if they become worse, check with your doctor.

This medicine may cause a serious allergic reaction called anaphylaxis. Anaphylaxis can be life-threatening and requires immediate medical attention. Call your doctor right away if you have a skin rash; itching; shortness of breath; trouble with breathing; trouble with swallowing; or any swelling of your hands, face, mouth, or throat after you or your child receive this medicine.

Amoxicillin may cause diarrhea, and in some cases it can be severe. It may occur 2 months or more after you stop taking this medicine. Do not take any medicine or give medicine to your child to treat diarrhea without first checking with your doctor. Diarrhea medicines may make the diarrhea worse or make it last longer. If you have any questions about this or if mild diarrhea continues or gets worse, check with your doctor.

Before you have any medical tests, tell the doctor in charge that you or your child are taking this medicine. The results of some tests may be affected by this medicine.

In some young patients, tooth discoloration may occur while using this medicine. The teeth may appear to have brown, yellow, or gray stains. To help prevent this, brush and floss your teeth regularly or have a dentist clean your teeth.

Birth control pills may not work while you are using this medicine. To keep from getting pregnant, use another form of birth control along with your birth control pills. Other forms include a condom, a diaphragm, or a contraceptive foam or jelly.

Do not take other medicines unless they have been discussed with your doctor. This includes prescription or nonprescription (over-the-counter [OTC]) medicines and herbal or vitamin supplements.

Riva-Amoxicillin Side Effects

Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur:

Incidence not known

• Abdominal or stomach cramps or tenderness


• back, leg, or stomach pains


• black, tarry stools


• bleeding gums


• blistering, peeling, or loosening of the skin


• bloating


• blood in the urine


• bloody nose


• chest pain


• chills


• clay-colored stools


• cough


• dark urine


• diarrhea


• diarrhea, watery and severe, which may also be bloody


• difficulty with breathing


• difficulty with swallowing


• dizziness


• fast heartbeat


• feeling of discomfort


• fever


• general body swelling


• headache


• heavier menstrual periods


• hives or welts


• increased thirst


• inflammation of the joints


• itching


• joint or muscle pain


• loss of appetite


• muscle aches


• nausea or vomiting


• nosebleeds


• pain


• pain in the lower back


• pain or burning while urinating


• painful or difficult urination


• pale skin


• pinpoint red spots on the skin


• puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue


• rash


• red, irritated eyes


• redness, soreness, or itching skin


• shortness of breath


• sore throat


• sores, ulcers, or white spots in the mouth or on the lips


• sores, welting, or blisters


• sudden decrease in the amount of urine


• swollen, lymph glands


• tenderness


• tightness in the chest


• unpleasant breath odor


• unusual bleeding or bruising


• unusual tiredness or weakness


• unusual weight loss


• vomiting of blood


• watery or bloody diarrhea


• wheezing


• yellow eyes or skin

Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

• Bad, unusual, or unpleasant (after) taste


• change in taste

Incidence not known

• Agitation


• black, hairy tongue


• changes in behavior


• confusion


• convulsions


• discoloration of the tooth (brown, yellow, or gray staining)


• dizziness


• sleeplessness


• trouble with sleeping


• unable to sleep


• white patches in the mouth or throat or on the tongue


• white patches with diaper rash

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.

The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.

Ferriprox

Ferriprox is a brand name of deferiprone, approved by the FDA in the following formulation(s):

FERRIPROX (deferiprone - tablet; oral)

• 
  Manufacturer: APOPHARMA INC
  
  Approval date: October 14, 2011
  
  Strength(s): 500MG ^[RLD]

Has a generic version of Ferriprox been approved?

No. There is currently no therapeutically equivalent version of Ferriprox available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ferriprox. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Ferriprox.

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • October 14, 2016 - NEW CHEMICAL ENTITY
  
  
  • October 14, 2018 - ORPHAN DRUG EXCLUSIVITY
  
  

See also...

• Ferriprox Consumer Information (Drugs.com)
• Ferriprox Consumer Information (Wolters Kluwer)
• Deferiprone Consumer Information (Wolters Kluwer)

Oxandrolone

Pronunciation: ox-AN-droe-lone
Generic Name: Oxandrolone
Brand Name: Oxandrin

Oxandrolone may cause cysts filled with blood in the liver or spleen, or liver tumors that may be fatal. These side effects may go unnoticed until life-threatening liver failure or internal bleeding develops. These side effects often stop or reverse when the medicine is stopped. Oxandrolone may also cause blood lipid (fat) changes that may increase the risk of hardening of the arteries and certain heart/blood vessel diseases (coronary artery disease).

Oxandrolone is used for:

Promoting weight gain, in combination with other medicines, after weight loss due to major surgery, recurring infections, serious injury, or unknown reasons. It is also used to offset certain side effects of long-term steroid use (protein catabolism), or to relieve bone pain due to osteoarthritis. It may also be used for other conditions as determined by your doctor.

Oxandrolone is an anabolic steroid. It works by helping the body to produce testosterone, which helps build muscle mass.

Do NOT use Oxandrolone if:

• you are allergic to any ingredient in Oxandrolone


• you are a man who has known or suspected breast or prostate cancer


• you are a woman who has breast cancer and high blood calcium levels


• you are pregnant


• you have certain kidney problems (nephrosis) or high blood calcium levels

Contact your doctor or health care provider right away if any of these apply to you.

Before using Oxandrolone:

Some medical conditions may interact with Oxandrolone. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

• if you are planning to become pregnant or are breast-feeding


• if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement


• if you have allergies to medicines, foods, or other substances


• if you have an enlarged prostate; heart, blood vessel, kidney, or liver disease; or breast cancer

Some MEDICINES MAY INTERACT with Oxandrolone. Tell your health care provider if you are taking any other medicines, especially any of the following:

• Anticoagulants (eg, warfarin), carbamazepine, or diabetes medicines (eg, glipizide) because the actions and side effects of these medicines may be increased


• Corticosteroids (eg, prednisone) or corticotropin because risk of serious side effects, including swelling, may be increased

This may not be a complete list of all interactions that may occur. Ask your health care provider if Oxandrolone may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

How to use Oxandrolone:

Use Oxandrolone as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• Oxandrolone may be taken with or without food.


• If you miss a dose of Oxandrolone, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Oxandrolone.

Important safety information:

• Oxandrolone has not been shown to enhance athletic ability. Do not take Oxandrolone for any reason other than that for which it was prescribed.


• Oxandrolone may reduce the number of certain clot-forming substances in your blood. To prevent bleeding, avoid situations in which bruising or injury may occur. Report any unusual bleeding, bruising, blood in stools, or dark, tarry stools to your doctor.


• Diabetes patients - Oxandrolone may affect your blood sugar. Check blood sugar levels closely and ask your doctor before adjusting the dose of your diabetes medicine.


• LAB TESTS, including liver function tests, blood cell counts, cholesterol levels, or blood calcium levels, may be performed to check for side effects. Be sure to keep all doctor and lab appointments.


• Use Oxandrolone with caution in the ELDERLY because they may be more sensitive to its effects, especially prostate problems (eg, enlargement, cancer), fluid buildup, or abnormal liver function tests.


• Use Oxandrolone with extreme caution in CHILDREN. Safety and effectiveness have not been confirmed.


• Oxandrolone may affect the bone growth rate in CHILDREN. Your child's bone growth should be checked every 6 months while using Oxandrolone.


• PREGNANCY and BREAST-FEEDING: Do not use Oxandrolone if you are pregnant. If you suspect that you could be pregnant, contact your doctor immediately. It is unknown if Oxandrolone is excreted in breast milk. Do not breast-feed while taking Oxandrolone.

When used for long periods of time or at high doses, some people develop a need to continue taking Oxandrolone. This is known as DEPENDENCE or addiction.

If you suddenly stop taking Oxandrolone, you may experience WITHDRAWAL symptoms, including depression, insomnia, loss of appetite, mood swings, reduced sex drive, restlessness, or tiredness.

Possible side effects of Oxandrolone:

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:

Difficulty sleeping.

Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); acne; changes in sexual desire; changes in skin color; confusion; dark urine; deepening of the voice, unusual hair growth (especially facial hair), or hoarseness; depression; easy bruising or bleeding; enlarged genitals or breasts; excitability; frequent or persistent erections; increased urination or thirst; irregular heartbeat; loss of appetite; menstrual irregularities; mental or mood changes; muscle cramps or twitching; nausea or vomiting; stomach pain; swelling of the ankles or hands; unusual tiredness; yellowing of the skin or eyes.

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.

See also: Oxandrolone side effects (in more detail)

If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately.

Proper storage of Oxandrolone:

Store Oxandrolone at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Oxandrolone out of the reach of children and away from pets.

General information:

• If you have any questions about Oxandrolone, please talk with your doctor, pharmacist, or other health care provider.


• Oxandrolone is to be used only by the patient for whom it is prescribed. Do not share it with other people.


• If your symptoms do not improve or if they become worse, check with your doctor.


• Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Oxandrolone. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.

Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Oxandrolone resources

• Oxandrolone Side Effects (in more detail)
• Oxandrolone Use in Pregnancy & Breastfeeding
• Drug Images
• Oxandrolone Drug Interactions
• Oxandrolone Support Group
• 0 Reviews for Oxandrolone - Add your own review/rating

• Oxandrolone Prescribing Information (FDA)


• Oxandrolone Monograph (AHFS DI)


• Oxandrolone Professional Patient Advice (Wolters Kluwer)


• oxandrolone Concise Consumer Information (Cerner Multum)


• Oxandrin Prescribing Information (FDA)

Compare Oxandrolone with other medications

• Alcoholic Liver Damage
• Turner's Syndrome
• Weight Loss

Verrutrix

Verrutrix may be available in the countries listed below.

Ingredient matches for Verrutrix

Salicylic Acid

Salicylic Acid is reported as an ingredient of Verrutrix in the following countries:

• Argentina

International Drug Name Search

Sophiren Ofteno

Sophiren Ofteno may be available in the countries listed below.

Ingredient matches for Sophiren Ofteno

Prednisolone

Prednisolone 21-acetate (a derivative of Prednisolone) is reported as an ingredient of Sophiren Ofteno in the following countries:

• Colombia

International Drug Name Search

Ulcerit

Ulcerit may be available in the countries listed below.

Ingredient matches for Ulcerit

Ranitidine

Ranitidine hydrochloride (a derivative of Ranitidine) is reported as an ingredient of Ulcerit in the following countries:

• Brazil

International Drug Name Search

Diclofenac Ecar

Diclofenac Ecar may be available in the countries listed below.

Ingredient matches for Diclofenac Ecar

Diclofenac

Diclofenac sodium salt (a derivative of Diclofenac) is reported as an ingredient of Diclofenac Ecar in the following countries:

• Colombia

International Drug Name Search

Yarvitan

Yarvitan may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Yarvitan

Mitratapide

Mitratapide is reported as an ingredient of Yarvitan in the following countries:

• Austria


• Belgium


• Finland


• France


• Germany


• Italy


• Netherlands


• Sweden

International Drug Name Search

Oxybutynine HCl Merck

Oxybutynine HCl Merck may be available in the countries listed below.

Ingredient matches for Oxybutynine HCl Merck

Oxybutynin

Oxybutynin hydrochloride (a derivative of Oxybutynin) is reported as an ingredient of Oxybutynine HCl Merck in the following countries:

• Netherlands

International Drug Name Search

Trizivir

Trizivir is a brand name of abacavir/lamivudine/zidovudine, approved by the FDA in the following formulation(s):

TRIZIVIR (abacavir sulfate; lamivudine; zidovudine - tablet; oral)

• 
  Manufacturer: VIIV HLTHCARE
  
  Approval date: November 14, 2000
  
  Strength(s): EQ 300MG BASE;150MG;300MG ^[RLD]

Has a generic version of Trizivir been approved?

No. There is currently no therapeutically equivalent version of Trizivir available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Trizivir. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Therapeutic nucleosides
  Patent 5,034,394
  Issued: July 23, 1991
  Inventor(s): Daluge; Susan M.
  Assignee(s): Burroughs Wellcome Co.
  The present invention relates to 6-substituted purine carbocyclic nucleosides and their use in medical therapy particularly in the treatment of HIV and HBV infections. Also provided are pharmaceutical formulations and processes for the preparation of compounds according to the invention.
  
  Patent expiration dates:
  
  
  • December 18, 2011
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • June 18, 2012
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Crystalline oxathiolane derivatives
  Patent 5,905,082
  Issued: May 18, 1999
  Inventor(s): Roberts; Tony Gordon & Evans; Paul
  Assignee(s): Glaxo Group Limited
  (-)cis-4-Amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(IH)-pyrimidine-2-on e in crystalline form, in particular as needle-shaped or bypyramidyl crystals, pharmaceutical formulations thereof, methods for their preparation and their use in medicine.
  
  Patent expiration dates:
  
  
  • May 18, 2016
    
    ✓ 
    Patent use: TREATMENT OF HIV
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • November 18, 2016
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Carbocyclic nucleoside hemisulfate and its use in treating viral infections
  Patent 6,294,540
  Issued: September 25, 2001
  Inventor(s): Brodie; Alastair Couper & Jones; Martin Francis & Seager; John Frederick & Wallis; Christopher John
  Assignee(s): Glaxo Wellcome Inc.
  The hemisulfate salt of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene- 1-methanol or a solvate of it is used in the treatment of viral infections.
  
  Patent expiration dates:
  
  
  • May 14, 2018
    
    ✓ 
    Patent use: METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • November 14, 2018
    
    ✓ 
    Patent use: METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV
    ✓ 
    Pediatric exclusivity
  
  



• 
  Synergistic combinations of zidovudine, 1592U89 and 3TC
  Patent 6,417,191
  Issued: July 9, 2002
  Inventor(s): David Walter; Barry & Martha Heider; St. Clair
  Assignee(s): GlaxoSmithKline
  The present invention relates to therapeutic combinations of (1S,4R)-cis-4-&lsqb;2-amino-6-(cyclopropylamino)-9H-purin-9-yl)-2-cyclopentene-1-methanol (1592U89), 3′-azido-3′-deoxythymidine (zidovudine) and (2R,cis)-4-amino-&rsqb;-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (3TC) (or, alternatively to 3TC, (2R,cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (FTC)) which have anti-HIV activity. The present invention is also concerned with pharmaceutical compositions containing said combinations and their use in the treatment of HIV infections including infections with HIV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors.
  
  Patent expiration dates:
  
  
  • March 28, 2016
    
    ✓ 
    Patent use: TREATMENT OF HIV
    ✓ 
    Drug product
  
  

See also...

• Trizivir Consumer Information (Drugs.com)
• Trizivir Consumer Information (Wolters Kluwer)
• Trizivir Consumer Information (Cerner Multum)
• Trizivir Advanced Consumer Information (Micromedex)
• Abacavir/Lamivudine/Zidovudine Consumer Information (Wolters Kluwer)
• Abacavir, lamivudine, and zidovudine Consumer Information (Cerner Multum)
• Abacavir-lamivudine-zidovudine Consumer Information (Cerner Multum)
• Abacavir, lamivudine, and zidovudine Advanced Consumer Information (Micromedex)

Felodipin-Mepha

Felodipin-Mepha may be available in the countries listed below.

Ingredient matches for Felodipin-Mepha

Felodipine

Felodipine is reported as an ingredient of Felodipin-Mepha in the following countries:

• Switzerland

International Drug Name Search

Oviskin

Oviskin may be available in the countries listed below.

Ingredient matches for Oviskin

Betamethasone

Betamethasone 17α,21-dipropionate (a derivative of Betamethasone) is reported as an ingredient of Oviskin in the following countries:

• Indonesia

International Drug Name Search

Advair HFA

See also: Generic Advair Diskus

Advair HFA is a brand name of fluticasone/salmeterol, approved by the FDA in the following formulation(s):

ADVAIR HFA (fluticasone propionate; salmeterol xinafoate - aerosol, metered; inhalation)

• 
  Manufacturer: GLAXOSMITHKLINE
  
  Approval date: June 8, 2006
  
  Strength(s): 0.045MG/INH;EQ 0.021MG BASE/INH ^[RLD], 0.115MG/INH;EQ 0.021MG BASE/INH ^[RLD], 0.23MG/INH;EQ 0.021MG BASE/INH ^[RLD]

Has a generic version of Advair HFA been approved?

No. There is currently no therapeutically equivalent version of Advair HFA available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Advair HFA. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Aerosol formulations containing propellant 134a and fluticasone propionate
  Patent 5,658,549
  Issued: August 19, 1997
  Inventor(s): Akehurst; Rachel Ann & Taylor; Anthony James & Wyatt; David Andrew
  Assignee(s): Glaxo Group Limited
  This invention relates to aerosol formulations of use for the administration of medicaments by inhalation, in particular a pharmaceutical aerosol formulation which comprises particulate medicament selected from the group comprising salmeterol, salbutamol, fluticasone propionate and physiologically acceptable salts and solvates thereof and a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant, which formulation is substantially free of surfactant. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation as defined is also described.
  
  Patent expiration dates:
  
  
  • August 19, 2014
    
    ✓ 
    Patent use: INDICATED FOR THE LONG-TERM, TWICE-DAILY MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 12 YEARS OF AGE OR OLDER
    ✓ 
    Drug product
  
  
  
  • February 19, 2015
    
    ✓ 
    Patent use: INDICATED FOR THE LONG-TERM, TWICE-DAILY MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 12 YEARS OF AGE OR OLDER
    ✓ 
    Pediatric exclusivity
  
  
  
  • February 19, 2015
    
    ✓ 
    Patent use: INDICATED FOR THE LONG-TERM, TWICE-DAILY MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 12 YEARS OF AGE OR OLDER
    ✓ 
    Pediatric exclusivity
    ✓ 
    Drug product
  
  



• 
  Canisters containing aerosol formulations containing P134a and fluticasone propionate
  Patent 5,674,472
  Issued: October 7, 1997
  Inventor(s): Akehurst; Rachel Ann & Taylor; Anthony James & Wyatt; David Andrew
  Assignee(s): Glaxo Group Limited
  The present invention relates to canisters suitable for delivering a pharmaceutical aerosol formulation which comprises a container capable of withstanding the vapor pressure of the propellant used, which container is closed with a metering valve and contains a pharmaceutical aerosol formulation consisting essentially of a particulate medicament which is fluticasone propionate or a physiologically acceptable solvate thereof and 1,1,1,2-tetrafluoroethane as propellant, which formulation contains less than 0.0001% w/w surfactant based on the weight of the medicament, the particulate medicament being present in an amount from 0.005% to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns. A further particulate medicament may also be present in the pharmaceutical aerosol formulation.
  
  Patent expiration dates:
  
  
  • October 7, 2014
    
    ✓ 
    Drug product
  
  
  
  • April 7, 2015
    
    ✓ 
    Pediatric exclusivity
  
  
  
  • April 7, 2015
    
    ✓ 
    Pediatric exclusivity
    ✓ 
    Drug product
  
  



• 
  Indicating device
  Patent 6,161,724
  Issued: December 19, 2000
  Inventor(s): Blacker; Richard & Engelbreth; Daniel K. & Schmidt; James N.
  Assignee(s): 1263152 Ontario Inc.
  An indicating device for use with a dispensing device that dispenses metered dosages of a medicament from a container having a valve moveable between an open and closed position. In a preferred embodiment, the container is reciprocally moveable within the housing along a longitudinal axis. The housing preferably has a well adapted to receive a valve stem and an exhaust port. The well communicates with the port such that the metered dosage of medicament is dispensed through the port when the valve is moved to the open position. An indicator assembly comprises an indicator member that includes dosage indicia visible to a user. In a preferred embodiment, the indicator assembly is provided in an indicator module. A method for dispensing measured dosages is also provided, along with a kit capable of being assembled as an inhalation device. A delivery system having a key member and a key entry passageway is also provided.
  
  Patent expiration dates:
  
  
  • January 16, 2018
    
    ✓ 
    Drug product
  
  
  
  • July 16, 2018
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Valve for aerosol container
  Patent 6,170,717
  Issued: January 9, 2001
  Inventor(s): Di Giovanni; Patrick & Rogerson; Cheryl Vanessa
  Assignee(s): Glaxo Wellcome Inc.
  Valve for an aerosol container for dispensing a suspension of a substance in a liquid propellant contained therein. The valve comprises a valve body (1) having at least one orifice (16) to allow a quantity of the suspension to pass from the container into the valve. The valve further comprises a ring (18) disposed around the valve body (1), the ring being positioned below the at least one orifice to reduce the volume of suspension that can be accommodated within the container below the at least one orifice when the container is orientated with the valve at the bottom, the ring having at least one portion of reduced axial thickness to provide a trough (19) around the valve body below the at least one orifice.
  
  Patent expiration dates:
  
  
  • December 23, 2017
    
    ✓ 
    Drug product
  
  
  
  • June 23, 2018
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Pharmaceutical aerosol formulation containing a particulate medicament, a propellant and substantially free of a surfactant
  Patent 6,251,368
  Issued: June 26, 2001
  Inventor(s): Akehurst; Rachel Ann & Taylor; Anthony James & Wyatt; David Andrew
  Assignee(s): Glaxo Group Limited
  A pharmaceutical aerosol formulation which comprises particulate medicament selected from the group consisting of salmeterol, salbutamol, fluticasone propionate, beclomethasone dipropionate and physiologically acceptable salts and solvates thereof and a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant, which formulation is substantially free of surfactant is disclosed. Also disclosed is a method of treating respiratory disorders which comprises administration by inhalation of an effective amount of the, pharmaceutical aerosol formulation which may be contained in a canister.
  
  Patent expiration dates:
  
  
  • December 4, 2012
    
    ✓ 
    Drug product
  
  
  
  • June 4, 2013
    
    ✓ 
    Pediatric exclusivity
  
  
  
  • June 4, 2013
    
    ✓ 
    Pediatric exclusivity
    ✓ 
    Drug product
  
  



• 
  Valve for aerosol container
  Patent 6,315,173
  Issued: November 13, 2001
  Inventor(s): Di Giovanni; Patrick & Rogerson; Cheryl Vanessa
  Assignee(s): SmithKline Beecham Corporation
  Valve for an aerosol container for dispensing a suspension of a substance in a liquid propellant contained therein The valve comprises a valve body (1) having at least one orifice (16) to allow a quantity of the suspension to pass from the container into the valve. The valve further comprises a ring (18) disposed around the valve body (1), the ring being positioned below the at least one orifice to reduce the volume of suspension that can be accommodated within the container below the at least one orifice when the container is orientated with the valve at the bottom, the ring having at least one portion of reduced axial thickness to provide a trough (19) around the valve body below the at least one orifice.
  
  Patent expiration dates:
  
  
  • December 23, 2017
    
    ✓ 
    Drug product
  
  
  
  • June 23, 2018
    
    ✓ 
    Pediatric exclusivity
  
  
  
  • June 23, 2018
    
    ✓ 
    Pediatric exclusivity
    ✓ 
    Drug product
  
  



• 
  Dispenser with doses′ counter
  Patent 6,431,168
  Issued: August 13, 2002
  Inventor(s): Paul Kenneth; Rand & Peter John; Brand & James William; Godfrey & Stanley George; Bonney
  Assignee(s): Smithkline Beecham Corporation
  There is provided a dispenser suitable for dispensing medicament, particularly medicament for use in the treatment of respiratory disorders. The dispenser comprises a housing (1) having a support (5); a container (2), locatable within said housing (1), having an outlet member, wherein said container (2) is movable relative to the housing (1) to enable dispensing therefrom and said outlet member is connectable with said support (5) to prevent relative movement there-between; and a dose indicator (13, 43), locatable within said housing (1). The container (2) and dose indicator (13, 43) are reversably removable from the housing (1) as a single unit.
  
  Patent expiration dates:
  
  
  • June 8, 2018
    
    ✓ 
    Drug product
  
  
  
  • December 8, 2018
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Delivery system for a medicament and method for the assembly thereof
  Patent 6,435,372
  Issued: August 20, 2002
  Inventor(s): Richard; Blacker & Daniel K.; Engelbreth & James N.; Schmidt
  Assignee(s): 1263152 Ontario Inc.
  An indicating device for use with a dispensing device that dispenses metered dosages of a medicament from a container having a valve moveable between an open and closed position. In a preferred embodiment, the container is reciprocally moveable within the housing along a longitudinal axis. The housing preferably has a well adapted to receive a valve stem and an exhaust port. The well communicates with the port such that the metered dosage of medicament is dispensed through the port when the valve is moved to the open position. An indicator assembly comprises an indicator member that includes dosage indicia visible to a user. In a preferred embodiment, the indicator assembly is provided in an indicator module. A method for dispensing measured dosages is also provided, along with a kit capable of being assembled as an inhalation device. A delivery system having a key member and a key entry passageway is also provided.
  
  Patent expiration dates:
  
  
  • January 16, 2018
    
    ✓ 
    Drug product
  
  
  
  • July 16, 2018
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Valve for aerosol container
  Patent 6,510,969
  Issued: January 28, 2003
  Inventor(s): Patrick; Di Giovanni & Cheryl Vanessa; Rogerson
  Assignee(s): SmithKline Beecham Corporation
  Valve for an aerosol container for dispensing a suspension of a substance in a liquid propellant contained therein. The valve comprises a valve body (1) having at least one orifice (16) to allow a quantity of the suspension to pass from the container into the valve. The valve further comprises a ring (18) disposed around the valve body (1), the ring being positioned below the at least one orifice to reduce the volume of suspension that can be accommodated within the container below the at least one orifice when the container is orientated with the valve at the bottom, the ring having at least one portion of reduced axial thickness to provide a trough (19) around the valve body below the at least one orifice.
  
  Patent expiration dates:
  
  
  • December 23, 2017
    
  
  
  
  • December 23, 2017
    
    ✓ 
    Drug product
  
  
  
  • June 23, 2018
    
    ✓ 
    Pediatric exclusivity
  
  
  
  • June 23, 2018
    
    ✓ 
    Pediatric exclusivity
    ✓ 
    Drug product
  
  



• 
  Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol
  Patent 6,596,260
  Issued: July 22, 2003
  Inventor(s): Fran&ccedil;ois; Brugger & Angelika; Stampf
  Assignee(s): Novartis Corporation
  The invention relates to an aerosol container for pharmaceutically active aerosols that are to be administered in predetermined amounts and that are supplied in the container in the form of a suspension, the suspension also comprising, in addition to a pharmaceutically active substance, at least a propellant gas. The aerosol container has a metering valve that comprises a metering chamber and a valve stem. In a first position of the valve stem, the metering chamber is in communication with the interior of the container and has been filled with a predetermined amount of the aerosol. In a second position of the valve stem, the amount of aerosol disposed in the metering chamber is released. The propellant gas is an alternative propellant gas that is free of fluorochlorohydrocarbons, preferably a propellant gas that comprises only fluorohydrocarbons, and the inner wall of the container is coated with a plastics coating.
  
  Patent expiration dates:
  
  
  • August 10, 2014
    
    ✓ 
    Drug product
  
  
  
  • February 10, 2015
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Suspension aerosol formulations
  Patent 6,743,413
  Issued: June 1, 2004
  Inventor(s): Robert K.; Schultz & David W.; Schultz & Martin J.; Oliver & Robert A.; Moris & Philip A.; Jinks
  Assignee(s): 3M Company
  Pharmaceutical suspension aerosol formulations containing a therapeutically effective amount of a drug and HFC 134a, HFC 227, or a mixture thereof.
  
  Patent expiration dates:
  
  
  • June 1, 2021
    
    ✓ 
    Patent use: INDICATED FOR THE LONG-TERM, MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 12 YEARS OF AGE AND OLDER
  
  
  
  • December 1, 2021
    
    ✓ 
    Patent use: INDICATED FOR THE LONG-TERM, MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 12 YEARS OF AGE AND OLDER
    ✓ 
    Pediatric exclusivity
  
  



• 
  Indicating device
  Patent 6,938,796
  Issued: September 6, 2005
  Inventor(s): Blacker; Richard & Engelbreth; Daniel K. & Schmidt; James N.
  Assignee(s): 1263152 Ontario Inc.
  A device for dispensing metered dosages of a substance from a container includes a dispenser housing and an indicating device. The indicating device includes an indicator housing, at least one engagement member disposed in the indicator housing, a plurality of indicator members coaxially mounted in the indicator housing, and an actuator coupled to and moveable with the container relative to the plurality of indicator members and the dispenser housing. The actuator member is selectively engaged with at least one of indicator members and is operative to advance the at least one indicator member an incremental amount. The at least one engagement member is selectively engaged with an advancement member so as to bias the advancement member into operable engagement with at least one of the indicator members and move the at least one indicator member an incremental amount. A method for dispensing metered dosages of the substance is also provided.
  
  Patent expiration dates:
  
  
  • January 16, 2018
    
    ✓ 
    Drug product
  
  
  
  • July 16, 2018
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Valve for aerosol container
  Patent 6,966,467
  Issued: November 22, 2005
  Inventor(s): Di Giovanni; Patrick & Rogerson; Cheryl Vanessa
  Assignee(s): SmithKlineBeecham Corporation
  Valve for an aerosol container for dispensing a suspension of a substance in a liquid propellant contained therein. The valve comprises a valve body (1) having at least one orifice (16) to allow a quantity of the suspension to pass from the container into the valve. The valve further comprises a ring (18) disposed around the valve body (1), the ring being positioned below the at least one orifice to reduce the volume of suspension that can be accommodated within the container below the at least one orifice when the container is orientated with the valve at the bottom, the ring having at least one portion of reduced axial thickness to provide a trough (19) around the valve body below the at least one orifice.
  
  Patent expiration dates:
  
  
  • December 23, 2017
    
    ✓ 
    Drug product
  
  
  
  • June 23, 2018
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Indicating device
  Patent 6,997,349
  Issued: February 14, 2006
  Inventor(s): Blacker; Richard & Engelbreth; Daniel K. & Schmidt; James N.
  Assignee(s): Trudell Medical International
  A dispenser for dispensing metered dosages of a substance from a container includes a dispenser housing having a top, a bottom, a longitudinally extending cavity open at the top, and a support block extending from the bottom into the cavity. The container includes an end portion, a valve stem extending from the end portion and a valve moveable between a closed position and an open position. An indicating device is disposed in the cavity of the dispenser housing. The indicating device includes a collar disposed around and secured to the end portion of the container and an indicator including dosage indicia. The indicator is disposed in the cavity beneath the end portion of the container
  
  Patent expiration dates:
  
  
  • January 16, 2018
    
    ✓ 
    Drug product
  
  
  
  • July 16, 2018
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Dispenser with doses' counter
  Patent 7,107,986
  Issued: September 19, 2006
  Inventor(s): Rand; Paul Kenneth & Brand; Peter John & Godfrey; James William
  Assignee(s): Glaxo Group Limited
  There is provided a dispenser suitable for dispensing medicament, particularly medicament for use in the treatment of respiratory disorders. The dispenser comprises a housing having a support; a container, locatable within said housing, having an outlet, wherein said container dispenses through said outlet in response to movement of the container relative to the housing; and an actuation indicator having an indexing mechanism actuatable by movement of the container relative to the housing. A couple mechanism is provided which couples the indexing mechanism to the container to compensate for any variation in pre-actuation positionings of the indexing mechanism and container.
  
  Patent expiration dates:
  
  
  • June 8, 2018
    
    ✓ 
    Drug product
  
  
  
  • December 8, 2018
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Indicating device
  Patent 7,143,908
  Issued: December 5, 2006
  Inventor(s): Blacker; Richard & Engelbreth; Daniel K. & Schmidt; James N.
  Assignee(s): Trudell Medical International
  A device for dispensing metered dosages of a substance from a container includes a dispenser housing having a longitudinally extending cavity defined at least in part by a wall and a support block spaced from the wall. The container is disposed in the cavity of the dispenser housing and is container reciprocally moveable within the dispenser housing along a longitudinal axis. An indicating device is disposed in the dispenser housing and includes an annular member disposed around a first end of the container with a valve stem of the container extending beyond the annular member. The indicating device includes at least one indicator member rotatable about an axis of rotation. At least a portion of the indicating device is fixedly connected to the container and is reversibly removable with the container from the dispenser housing.
  
  Patent expiration dates:
  
  
  • January 16, 2018
    
    ✓ 
    Drug product
  
  
  
  • July 16, 2018
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Valve for aerosol container
  Patent 7,350,676
  Issued: April 1, 2008
  Inventor(s): Di Giovanni; Patrick & Rogerson; Cheryl Vanessa
  Assignee(s): SmithKline Beecham Corporation
  Valve for an aerosol container for dispensing a suspension of a substance in a liquid propellant contained therein. The valve comprises a valve body (1) having at least one orifice (16) to allow a quantity of the suspension to pass from the container into the valve. The valve further comprises a ring (18) disposed around the valve body (1), the ring being positioned below the at least one orifice to reduce the volume of suspension that can be accommodated within the container below the at least one orifice when the container is orientated with the valve at the bottom, the ring having at least one portion of reduced axial thickness to provide a trough (19) around the valve body below the at least one orifice.
  
  Patent expiration dates:
  
  
  • August 24, 2018
    
    ✓ 
    Drug product
  
  
  
  • February 24, 2019
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Actuation indicator for a dispensing device
  Patent 7,500,444
  Issued: March 10, 2009
  Inventor(s): Bonney; Stanley George & Brand; Peter John & Godfrey; James William & Rand; Paul Kenneth
  Assignee(s): Glaxo Group Limited
  An actuation indicator that includes a drum sub-assembly, which includes a rotatable actuation indicator wheel, a rocking, ratchet pawl for rotating the indicator wheel in a set direction and a rocking mechanism for the pawl driven by a slipping clutch arrangement, is described. The slipping clutch arrangement includes a slipping clutch spring engaged at one end to a pinion of a rack and pinion assembly and at a second end to the ratchet pawl.
  
  Patent expiration dates:
  
  
  • January 4, 2025
    
    ✓ 
    Drug product
  
  
  
  • July 4, 2025
    
    ✓ 
    Pediatric exclusivity
  
  

See also...

• Advair HFA Inhaler Consumer Information (Wolters Kluwer)
• Advair HFA Consumer Information (Cerner Multum)
• Advair HFA Advanced Consumer Information (Micromedex)
• Advair Inhalation Aerosol Advanced Consumer Information (Micromedex)
• Fluticasone/Salmeterol Inhaler Consumer Information (Wolters Kluwer)
• Fluticasone/Salmeterol Powder Consumer Information (Wolters Kluwer)
• Fluticasone and salmeterol Consumer Information (Cerner Multum)
• Fluticasone and salmeterol Inhalation, oral/nebulization Advanced Consumer Information (Micromedex)